To explore strategies for improving the performance of CAR-NK cell therapies through receptor architecture and controlled drug exposure.
Key Findings:
All engineered CAR-NK cells demonstrated antigen-specific killing of CD19-positive leukemia and lymphoma cell lines.
Transcriptional profiling indicated different configurations engaged NK-associated activation programs variably.
Transient dasatinib exposure suppressed CAR-NK activity during treatment but enhanced cytotoxicity and cytokine production post-withdrawal.
2B4-based signaling elements in CAR-NK cells showed stronger tumor control and prolonged survival in mouse models.
Interpretation:
The study suggests that both the design of the CAR construct and the modulation of signaling activity can significantly influence the antitumor efficacy of CAR-NK therapies.
Limitations:
The study was conducted in a proof-of-concept NK-92 platform, which may not fully represent in vivo conditions.
Further research is needed to validate findings in clinical settings.
Conclusion:
Signaling architecture and reversible pharmacologic modulation could inform the design of next-generation allogeneic NK products.
